<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00468299</url>
  </required_header>
  <id_info>
    <org_study_id>H-25999</org_study_id>
    <nct_id>NCT00468299</nct_id>
  </id_info>
  <brief_title>MiMi: A Randomized Trial of Mifepristone and Misoprostol for Treatment of Early Pregnancy Failure</brief_title>
  <acronym>MiMi</acronym>
  <official_title>Treatment of Early Pregnancy Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare two combinations of drugs (mifepristone and
      misoprostol versus placebo and misoprostol) used for medical treatment for early pregnancy
      failure. We will compare the two combinations of medications to see which combination makes
      miscarriage happen faster. We hypothesize that there will be no difference in time to
      complete miscarriage between the two groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The optimal method of treating Early Pregnancy Failure (EPF) is not certain. For many years,
      surgical management of EPF was the only treatment option. Now there are multiple studies
      demonstrating the effectiveness of misoprostol for treating EPF. Most of the studies
      investigating medical treatment of EPF have evaluated efficacy at one week. We have found
      that many women do not want to wait for one week for an outcome of their medical treatment,
      and want resolution sooner. This has hampered the widespread utilization of medical therapy
      in our institution.

      We propose a regimen of medical treatment for EPF with expeditious follow-up. We want to
      demonstrate the relative efficacy of two medication regimens for treatment of EPF by
      performing a randomized trial. One regimen will be 800μg buccal misoprostol alone and the
      other regimen will be 200mg mifepristone, orally, in addition to 800μg buccal misoprostol,
      simultaneously. The primary outcome will be complete abortion rates 24hours after medication
      administration. We hypothesize that mifepristone will not improve complete abortion rates at
      24hrs.

      Secondary outcomes include rates of abortion by medical treatment at one week, the
      indications for surgical intervention, relationship of progesterone levels and type of
      pregnancy failure to outcomes in the two groups. Another secondary objective is to assess
      satisfaction with the treatment process at the conclusion of pregnancy termination, and 3
      weeks after the beginning of the process.

      The majority of studies investigating medical treatment of EPF use vaginal misoprostol, but
      buccal use is increasing. We will use buccal misoprostol, which is widely used at our
      institution. We will assess the efficacy of this route of administration as well as assess
      patient acceptability of this method.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment
  </why_stopped>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Women With Complete Abortion 24-48hrs After Receiving Medical Treatment for Early Pregnancy Failure.</measure>
    <time_frame>24-48 hrs</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Abortion at One Week</measure>
    <time_frame>3 weeks</time_frame>
    <description>Complete abortion at one week; uterus demonstrated to be empty on transvaginal ultrasound</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Early Pregnancy Failure</condition>
  <condition>Miscarriage</condition>
  <condition>Fetal Demise</condition>
  <condition>Anembryonic Pregnancy</condition>
  <arm_group>
    <arm_group_label>Misoprostol and placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Women in this arm receive placebo and misoprostol 800 mcg buccally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mifepristone and misoprostol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Womwn in this group receive mifepristone 200 mg orally and misoprostol 800 mcg buccally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Misoprostol and placebo</intervention_name>
    <description>Women in this group receive 800 mcg misoprostol plus a placebo</description>
    <arm_group_label>Misoprostol and placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mifepristone and misoprostol</intervention_name>
    <description>This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally</description>
    <arm_group_label>Mifepristone and misoprostol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;18yrs, able to read and write English

          -  Intrauterine gestations with anembryonic sac between 10 and 45mm or

          -  10-15mm sac with no growth in three days or other radiologic signs of abnormal
             pregnancy such as irregular sac or debris within the gestational sac

          -  An embryonic pole &lt;30mm with no cardiac activity

        Exclusion Criteria:

          -  Intrauterine gestations with CRL &lt;5mm or &gt;30mm without cardiac activity

          -  Incomplete abortion as defined as open cervix and large amount of cramping/bleeding

          -  Hemodynamic instability and/or heavy vaginal bleeding

          -  Hemoglobin less than or equal to 8

          -  Inability to follow-up (ie, lack of transportation or access to telephone)

          -  Bleeding disorder or taking anticoagulants

          -  Prior medical or surgical treatment of the current pregnancy

          -  Obvious Infection

          -  Active Lactation

          -  Allergy to mifepristone or misoprostol

          -  Chronic corticosteroid use

          -  Severe gastrointestinal disease (e.g inflammatory bowel disease, severe gastritis)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah J Betstadt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Olivera Vragovic, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Bagratee JS, Khullar V, Regan L, Moodley J, Kagoro H. A randomized controlled trial comparing medical and expectant management of first trimester miscarriage. Hum Reprod. 2004 Feb;19(2):266-71.</citation>
    <PMID>14747165</PMID>
  </reference>
  <reference>
    <citation>Creinin MD, Schwartz JL, Guido RS, Pymar HC. Early pregnancy failure--current management concepts. Obstet Gynecol Surv. 2001 Feb;56(2):105-13. Review.</citation>
    <PMID>11219590</PMID>
  </reference>
  <reference>
    <citation>Lelaidier C, Saint-Mleux CB, Fernandez H, Bourget P, Frydman R. [Embryo expulsion induction in first trimester miscarriages. Use of mifepristone (RU 486) in a double blind prospective randomized study]. Contracept Fertil Sex. 1993 Jun;21(6):505-8. French.</citation>
    <PMID>7920940</PMID>
  </reference>
  <reference>
    <citation>Lister MS, Shaffer LE, Bell JG, Lutter KQ, Moorma KH. Randomized, double-blind, placebo-controlled trial of vaginal misoprostol for management of early pregnancy failures. Am J Obstet Gynecol. 2005 Oct;193(4):1338-43.</citation>
    <PMID>16202723</PMID>
  </reference>
  <reference>
    <citation>Meckstroth KR, Whitaker AK, Bertisch S, Goldberg AB, Darney PD. Misoprostol administered by epithelial routes: Drug absorption and uterine response. Obstet Gynecol. 2006 Sep;108(3 Pt 1):582-90.</citation>
    <PMID>16946218</PMID>
  </reference>
  <reference>
    <citation>Middleton T, Schaff E, Fielding SL, Scahill M, Shannon C, Westheimer E, Wilkinson T, Winikoff B. Randomized trial of mifepristone and buccal or vaginal misoprostol for abortion through 56 days of last menstrual period. Contraception. 2005 Nov;72(5):328-32. Epub 2005 Aug 9.</citation>
    <PMID>16246656</PMID>
  </reference>
  <reference>
    <citation>Nielsen S, Hahlin M, Platz-Christensen JJ. Unsuccessful treatment of missed abortion with a combination of an antiprogesterone and a prostaglandin E1 analogue. Br J Obstet Gynaecol. 1997 Sep;104(9):1094-6.</citation>
    <PMID>9307543</PMID>
  </reference>
  <reference>
    <citation>Schaff EA, DiCenzo R, Fielding SL. Comparison of misoprostol plasma concentrations following buccal and sublingual administration. Contraception. 2005 Jan;71(1):22-5.</citation>
    <PMID>15639067</PMID>
  </reference>
  <reference>
    <citation>Stockheim D, Machtinger R, Wiser A, Dulitzky M, Soriano D, Goldenberg M, Schiff E, Seidman DS. A randomized prospective study of misoprostol or mifepristone followed by misoprostol when needed for the treatment of women with early pregnancy failure. Fertil Steril. 2006 Oct;86(4):956-60.</citation>
    <PMID>17027362</PMID>
  </reference>
  <reference>
    <citation>Tang OS, Schweer H, Seyberth HW, Lee SW, Ho PC. Pharmacokinetics of different routes of administration of misoprostol. Hum Reprod. 2002 Feb;17(2):332-6.</citation>
    <PMID>11821273</PMID>
  </reference>
  <reference>
    <citation>Trinder J, Brocklehurst P, Porter R, Read M, Vyas S, Smith L. Management of miscarriage: expectant, medical, or surgical? Results of randomised controlled trial (miscarriage treatment (MIST) trial). BMJ. 2006 May 27;332(7552):1235-40. Epub 2006 May 17.</citation>
    <PMID>16707509</PMID>
  </reference>
  <reference>
    <citation>Wagaarachchi PT, Ashok PW, Smith NC, Templeton A. Medical management of early fetal demise using sublingual misoprostol. BJOG. 2002 Apr;109(4):462-5.</citation>
    <PMID>12013170</PMID>
  </reference>
  <reference>
    <citation>Wagaarachchi PT, Ashok PW, Narvekar N, Smith NC, Templeton A. Medical management of early fetal demise using a combination of mifepristone and misoprostol. Hum Reprod. 2001 Sep;16(9):1849-53.</citation>
    <PMID>11527887</PMID>
  </reference>
  <reference>
    <citation>Zhang J, Gilles JM, Barnhart K, Creinin MD, Westhoff C, Frederick MM; National Institute of Child Health Human Development (NICHD) Management of Early Pregnancy Failure Trial. A comparison of medical management with misoprostol and surgical management for early pregnancy failure. N Engl J Med. 2005 Aug 25;353(8):761-9.</citation>
    <PMID>16120856</PMID>
  </reference>
  <reference>
    <citation>Zieman M, Fong SK, Benowitz NL, Banskter D, Darney PD. Absorption kinetics of misoprostol with oral or vaginal administration. Obstet Gynecol. 1997 Jul;90(1):88-92.</citation>
    <PMID>9207820</PMID>
  </reference>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2007</study_first_submitted>
  <study_first_submitted_qc>May 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2007</study_first_posted>
  <results_first_submitted>April 12, 2011</results_first_submitted>
  <results_first_submitted_qc>June 23, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 21, 2011</results_first_posted>
  <last_update_submitted>June 23, 2011</last_update_submitted>
  <last_update_submitted_qc>June 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sarah Betstadt, MD</name_title>
    <organization>University of Rochester Medical Center</organization>
  </responsible_party>
  <keyword>early</keyword>
  <keyword>pregnancy</keyword>
  <keyword>failure</keyword>
  <keyword>mifepristone</keyword>
  <keyword>misoprostol</keyword>
  <keyword>buccal</keyword>
  <keyword>miscarriage</keyword>
  <keyword>fetal</keyword>
  <keyword>demise</keyword>
  <keyword>anembryonic</keyword>
  <keyword>progesterone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abortion, Spontaneous</mesh_term>
    <mesh_term>Fetal Death</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Misoprostol</mesh_term>
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Misoprostol and Placebo</title>
          <description>Women in this groups received misoprostol (800 mcg buccally) plus a placebo for treatment of early pregnancy failure.</description>
        </group>
        <group group_id="P2">
          <title>Mifepristone and Misoprostol</title>
          <description>Women in this group received mifepristone 200 mg orally followed by misoprostol 800 mcg buccally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Misoprostol and Placebo</title>
          <description>Women in this groups received misoprostol (800 mcg buccally) plus a placebo for treatment of early pregnancy failure.</description>
        </group>
        <group group_id="B2">
          <title>Mifepristone and Misoprostol</title>
          <description>Women in this group received mifepristone 200 mg orally followed by misoprostol 800 mcg buccally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="4"/>
                    <measurement group_id="B2" value="29" spread="4"/>
                    <measurement group_id="B3" value="28" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Women With Complete Abortion 24-48hrs After Receiving Medical Treatment for Early Pregnancy Failure.</title>
        <time_frame>24-48 hrs</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol and Placebo</title>
            <description>Women in this groups received misoprostol (800 mcg buccally) plus a placebo for treatment of early pregnancy failure.</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone and Misoprostol</title>
            <description>Women in this group received mifepristone 200 mg orally followed by misoprostol 800 mcg buccally</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Women With Complete Abortion 24-48hrs After Receiving Medical Treatment for Early Pregnancy Failure.</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Complete Abortion at One Week</title>
        <description>Complete abortion at one week; uterus demonstrated to be empty on transvaginal ultrasound</description>
        <time_frame>3 weeks</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Misoprostol and Placebo</title>
            <description>Women received a placebo followed by misoprostol 800 mcg buccally</description>
          </group>
          <group group_id="O2">
            <title>Mifepristone and Misoprostol</title>
            <description>Women received mifeppristone 200 mg orally followed ny misoprostol 800 mcg buccally</description>
          </group>
        </group_list>
        <measure>
          <title>Complete Abortion at One Week</title>
          <description>Complete abortion at one week; uterus demonstrated to be empty on transvaginal ultrasound</description>
          <population>Per protocol</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Misoprostol and Placebo</title>
          <description>Women in this groups received misoprostol (800 mcg buccally) plus a placebo for treatment of early pregnancy failure.</description>
        </group>
        <group group_id="E2">
          <title>Mifepristone and Misoprostol</title>
          <description>Women in this group received mifepristone 200 mg orally followed by misoprostol 800 mcg buccally</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated because of poor enrollment. Few eligible women were referred.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sarah Betstadt</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-276-5368</phone>
      <email>sarah_betstadt@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

